ADVENTRX Pharmaceuticals Provides Update on ANX-514
ADVENTRX Pharmaceuticals, Inc. (NYSE: ANX) today provided an update on its product candidate, ANX-514, its polysorbate 80-free formulation of docetaxel.
The U.S. Food and Drug Administration (FDA) determined that ANX-514 could not be approved based on the findings from the bioequivalence study of ANX-514 (Study 514-01) and that additional development activities would be required for approval. ADVENTRX met with the FDA to discuss required activities.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.